Armodafinil (CEP-10953) in Treatment of Excessive Sleepiness Associated With Obstructive Sleep Apnea/Hypopnea (OSA/H) Syndrome

This study has been completed.
Sponsor:
Information provided by:
Teva Pharmaceutical Industries
ClinicalTrials.gov Identifier:
NCT00079677
First received: March 10, 2004
Last updated: July 12, 2013
Last verified: July 2013
  Purpose

The primary objective of this study is to determine whether treatment with Armodafinil (CEP-10953) is more effective than placebo treatment for patients with residual excessive sleepiness associated with obstructive sleep apnea/hypopnea syndrome (OSAHS) by measuring mean sleep latency from the Maintenance of Wakefulness Test (MWT) (30 minute version) (average of 4 naps at 0900, 1100, 1300, and 1500) and by Clinical Global Impression of Change (CGI C) ratings (as related to general condition) at week 12 (or last postbaseline visit).


Condition Intervention Phase
Obstructive Sleep Apnea
Sleep Hypopnea
Drug: Armodafinil 150 mg/day
Drug: Placebo
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of CEP-10953 (150 mg/Day) as Treatment for Adults With Residual Excessive Sleepiness Associated With Obstructive Sleep Apnea/Hypopnea Syndrome

Resource links provided by NLM:


Further study details as provided by Teva Pharmaceutical Industries:

Primary Outcome Measures:
  • Maintenance of Wakefulness Test (MWT) [ Time Frame: Change from baseline at 12 weeks or early termination ] [ Designated as safety issue: No ]
    The Maintenance of Wakefulness Test (MWT) is an objective assessment of sleepiness that measures the ability of a subject to remain awake. Long latencies to sleep are indicative of a patient's ability to remain awake. The change from baseline in the mean sleep latency from the MWT (average of 4 tests at 0900, 1100, 1300, and 1500) was analyzed at weeks 4, 8, and 12. The primary efficacy variable was the mean change from the baseline assessment in MWT sleep latency as assessed at week 12 (or last post-baseline visit).

  • Number of Participants Who Had at Least Minimal Improvement in CGI-C Ratings at Week 12 or Last Post-baseline Visit. [ Time Frame: 12 weeks or last post-baseline visit ] [ Designated as safety issue: No ]
    Number of participants who had at least minimal improvement in CGI-C ratings at Week 12 or last post-baseline visit. The CGI-C uses the following categories and scoring assignments: 1=Very much improved; 2=Much improved; 3=Minimally improved; 4=No change; 5=Minimally worse; 6=Much worse; and 7=Very much worse. Severity of illness was assessed at baseline by the CGI-S, which consists of the following categories: 1=Normal (shows no signs of illness); 2=Borderline ill; 3=Mildly (Slightly) ill; 4=Moderately ill; 5=Markedly ill; 6=Severely ill; and 7=Among the most extremely ill patients.


Enrollment: 263
Study Start Date: March 2004
Estimated Study Completion Date: October 2004
Arms Assigned Interventions
Experimental: 1
Armodafinil 150 mg/day
Drug: Armodafinil 150 mg/day
Armodafinil 150 mg once daily in the morning
Placebo Comparator: 2
Placebo
Drug: Placebo
Matching placebo tablets once daily

  Eligibility

Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Diagnosis and Criteria for Inclusion: Patients are included in the study if all of the following criteria are met:

  1. Written informed consent is obtained.
  2. The patient is an outpatient, man or woman of any ethnic origin, 18 to 65 years of age (inclusive).
  3. The patient has a complaint of excessive sleepiness despite nCPAP therapy being effective and being a regular user of nCPAP therapy.
  4. The patient has a current diagnosis of OSAHS according to International Classification of Sleep Disorders (ICSD) criteria.
  5. The patient meets the following nCPAP therapy requirements:

    • Adequate education and intervention efforts to encourage nCPAP therapy use must be documented.
    • A patient's nCPAP therapy regimen must be stable for at least 4 weeks.
    • nCPAP therapy is shown to be effective, with effectiveness defined as having an apnea hypopnea index (AHI) of 10 or less during nocturnal PSG, and, in the opinion of the investigator, nCPAP is effective therapy.
    • Following demonstration of effectiveness, evidence of regular nCPAP usage must be shown during a 2 week evaluation period (ie, nCPAP usage for at least 4 hours/night on at least 70% of the nights).
  6. The patient is in good health as determined by a medical and psychiatric history, physical examination, ECG, and serum chemistry and hematology.
  7. Women must be surgically sterile, 2 years postmenopausal, or, if of child bearing potential, using a medically accepted method of birth control (ie, barrier method with spermicide, steroidal contraceptive [oral, implanted, and Depo Provera contraceptives must be used in conjunction with a barrier method], or intrauterine device [IUD]) and agree to continued use of this method for the duration of the study.
  8. The patient has a Clinical Global Impression of Severity of Illness (CGI S) rating of 4 or more.
  9. The patient has an ESS score of 10 or more.
  10. The patient does not have any medical or psychiatric disorders that could account for the excessive sleepiness.
  11. The patient is able to complete self rating scales and computer based testing.
  12. The patient is willing and able to comply with study restrictions and to attend regularly scheduled clinic visits as specified in this protocol.

Criteria for Exclusion: Patients are excluded from participating in this study if 1 or more of the following criteria are met:

  1. has any clinically significant, uncontrolled medical or psychiatric conditions (treated or untreated)
  2. has a probable diagnosis of a current sleep disorder other than OSAHS
  3. consumes caffeine including coffee, tea and/or other caffeine containing beverages or food averaging more than 600 mg of caffeine per day
  4. used any prescription drugs disallowed by the protocol or clinically significant use of over the counter (OTC) drugs within 14 days before the second screening visit
  5. has a history of alcohol, narcotic, or any other drug abuse as defined by the Diagnostic and Statistical Manual of Mental Disorders of the American Psychiatric Association, 4th Edition (DSM IV)
  6. has a positive urine drug screen (UDS)
  7. has a clinically significant deviation from normal in the physical examination
  8. is a pregnant or lactating woman. (Any woman becoming pregnant during the study will be withdrawn from the study.)
  9. has used an investigational drug within 1 month before the initial screening visit
  10. has any disorder that may interfere with drug absorption, distribution, metabolism, or excretion (including gastrointestinal surgery)
  11. has a known clinically significant drug sensitivity to stimulants or modafinil
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

No Contacts or Locations Provided
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00079677     History of Changes
Other Study ID Numbers: C10953/3025/AP/MN
Study First Received: March 10, 2004
Results First Received: June 1, 2009
Last Updated: July 12, 2013
Health Authority: United States: Food and Drug Administration

Keywords provided by Teva Pharmaceutical Industries:
Excessive Sleepiness
Obstructive Sleep Apnea
Obstructive Sleep Hypopnea
nCPAP
Cephalon
Cephalon, Inc
Nuvigil

Additional relevant MeSH terms:
Apnea
Sleep Apnea Syndromes
Sleep Apnea, Obstructive
Respiration Disorders
Respiratory Tract Diseases
Signs and Symptoms, Respiratory
Signs and Symptoms
Sleep Disorders, Intrinsic
Dyssomnias
Sleep Disorders
Nervous System Diseases
Armodafinil
Modafinil
Wakefulness-Promoting Agents
Central Nervous System Stimulants
Central Nervous System Agents
Therapeutic Uses
Pharmacologic Actions
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on August 25, 2014